{
    "root": "e74e2e25-66da-4c49-9c26-44c409e14d40",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Bylvay",
    "value": "20250325",
    "ingredients": [
        {
            "name": "odevixibat",
            "code": "2W150K0UUC",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16261"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        }
    ],
    "indications": {
        "text": "bylvay ileal bile acid transporter ( ibat ) inhibitor indicated : progressive familial intrahepatic cholestasis ( pfic ) treatment pruritus patients 3 months age older progressive familial intrahepatic cholestasis ( pfic ) . ( 1.1 ) limitation : bylvay may effective subgroup pfic type 2 patients abcb11 variants resulting non-functional complete absence bile salt export pump protein . ( 1.1 , 12.5 , 14 ) alagille syndrome ( algs ) treatment cholestatic pruritus patients 12 months age older alagille syndrome ( algs ) . ( 1.2 )",
        "doid_entities": [
            {
                "text": "progressive familial intrahepatic cholestasis (DOID:0070221)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0070221"
            },
            {
                "text": "intrahepatic cholestasis (DOID:1852)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1852"
            },
            {
                "text": "cholestasis (DOID:13580)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13580"
            },
            {
                "text": "alagille syndrome (DOID:9245)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9245"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended pfic : patients 3 months older : 40 mcg/kg taken orally daily . ( 2.1 ) improvement pruritus 3 months , may increased 40 mcg/kg increments 120 mcg/kg daily , exceed daily 6 mg/day . ( 2.1 ) algs : patients 12 months older : 120 mcg/kg taken orally daily . ( 2.2 ) preparation instructions administer bylvay morning meal . ( 2.4 ) crush chew capsules . ( 2.4 ) full prescribing information preparation instructions . ( 2.4 )",
        "doid_entities": [
            {
                "text": "pfic (DOID:0070221)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0070221"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "ibat inhibitors , including bylvay , contraindicated patients prior active hepatic decompensation events ( e.g . , variceal hemorrhage , ascites , hepatic encephalopathy ) [ ( 5.1 ) ] .",
    "indications_original": "BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 1.1 , 12.5 , 14 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 )",
    "contraindications_original": "Recommended Dosage PFIC: Patients 3 months and older: 40 mcg/kg taken orally once daily. ( 2.1 ) If there is no improvement in pruritus after 3 months, the dosage may be increased in 40 mcg/kg increments up to 120 mcg/kg once daily, not to exceed a daily dosage of 6 mg/day. ( 2.1 ) ALGS: Patients 12 months and older: 120 mcg/kg taken orally once daily. ( 2.2 ) Preparation and Administration Instructions Administer BYLVAY in the morning with a meal. ( 2.4 ) Do not crush or chew capsules. ( 2.4 ) See full prescribing information for preparation and administration instructions. ( 2.4 )",
    "adverseReactions_original": "IBAT inhibitors, including BYLVAY, are contraindicated in patients with prior or active hepatic decompensation events (e.g., variceal hemorrhage, ascites, hepatic encephalopathy) [see Warnings and Precautions (5.1)].",
    "drug": [
        {
            "name": "Bylvay",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16261"
        }
    ]
}